Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study and School of Pharmaceutical Science, University of South China, Hengyang, China.
Tissue Eng Part B Rev. 2021 Oct;27(5):430-454. doi: 10.1089/ten.TEB.2020.0168. Epub 2020 Nov 25.
Despite tremendous progresses made in the field of tissue engineering over the past several decades, it remains a significant challenge for the treatment of osteoporosis (OP) due to the lack of appropriate carriers to improve the bioavailability of therapeutic agents and the unavailability of artificial bone matrix with desired properties for the replacement of damaged bone regions. Encouragingly, the development of injectable hydrogels for the treatment of OP has attracted increasing attention in recent years because they can serve either as a reservoir for various therapeutic species or as a perfect filler for bone injuries with irregular shapes. However, the relationship between the complicated pathological mechanism of OP and the properties of diverse polymeric materials lacks elucidation, which clearly hampers the clinical application of injectable hydrogels for the efficient treatment of OP. To clarify this relationship, this article summarized both localized and systematic treatment of OP using an injectable hydrogel-based strategy. Specifically, the pathogenesis of OP and the limitations of current treatment approaches were first analyzed. We further focused on the use of hydrogels loaded with various therapeutic substances following a classification standard of the encapsulated cargoes for OP treatment with an emphasis on the application and precautions of each category. A concluding remark on existing challenges and future directions of this rapidly developing research area was finally made. Impact statement Effective osteoporosis (OP) treatment remains a significant challenge due substantially to the unavailability of appropriate drug carriers and artificial matrices with desired properties to promote bone repair and replace damaged regions. For this purpose, this review focused on the development of diverse injectable hydrogel systems for the delivery of various therapeutic agents, including drugs, stem cells, and nucleic acids, for effective increase in bone mass and favorable osteogenesis. The summarized important guidelines are believed to promote clinical development and translation of hydrogels for the efficient treatment of OP and OP-related bone damages toward improved life quality of millions of patients.
尽管在过去几十年中,组织工程领域取得了巨大进展,但由于缺乏合适的载体来提高治疗剂的生物利用度,以及缺乏具有所需特性的人工骨基质来替代受损的骨区域,因此治疗骨质疏松症 (OP) 仍然是一个重大挑战。令人鼓舞的是,近年来,用于治疗 OP 的可注射水凝胶的发展引起了越来越多的关注,因为它们既可以作为各种治疗物质的储库,也可以作为形状不规则的骨损伤的完美填充剂。然而,OP 的复杂病理机制与各种聚合物材料的特性之间的关系尚不清楚,这显然阻碍了可注射水凝胶在 OP 高效治疗中的临床应用。为了阐明这种关系,本文总结了使用基于可注射水凝胶的策略对 OP 进行局部和系统治疗。具体来说,首先分析了 OP 的发病机制和当前治疗方法的局限性。我们进一步专注于使用各种治疗物质负载的水凝胶,根据封装货物的分类标准对 OP 治疗进行分类,重点介绍每一类别的应用和注意事项。最后对这个快速发展的研究领域的现有挑战和未来方向进行了总结。
影响陈述
有效的骨质疏松症 (OP) 治疗仍然是一个重大挑战,主要是因为缺乏合适的药物载体和具有所需特性的人工基质来促进骨修复和替代受损区域。为此,本综述重点介绍了各种可注射水凝胶系统的开发,用于输送各种治疗剂,包括药物、干细胞和核酸,以有效增加骨量并促进有利的成骨作用。总结的重要指南有望促进水凝胶在 OP 及相关骨损伤的高效治疗中的临床开发和转化,从而提高数百万患者的生活质量。